Physician profile
Theodore Hackl
NPI 1881857662
$1,486.32
in general payments reported to CMS, 2019-2025
13 companies · $67.02 in 2025
The $67.02 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $41.38 · 2021: $78.09 · 2022: $398 · 2023: $406 · 2024: $276 · 2025: $67.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $344.86 | 2020-2023 | |
| Abbvie INC. | $306.77 | 2022-2023 | |
| Alcon Vision LLC | $194.20 | 2019-2025 | Clareon, Unity |
| Bausch & Lomb Americas INC. | $113.65 | 2024 | Miebo, Xiidra |
| Biotissue Holdings INC. | $109.00 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $100.43 | 2019-2021 | |
| Allergan, INC. | $97.20 | 2019 | |
| Horizon Therapeutics Plc | $67.05 | 2022 | |
| Ivantis, INC | $47.59 | 2019-2020 | |
| Rxsight INC | $30.60 | 2021 | |
| Ocular Therapeutix, INC. | $25.62 | 2025 | Dextenza |
| Vantage Technology LLC | $25.55 | 2022 | |
| Amgen INC. | $23.80 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Hackl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.